Industry News
Pharmaceutical Industry News
In its 2,000-patient Proteus…
In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
China’s Rise in Drug Development Looms Over U.S.
Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.
After winning a broader FDA label…
After winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sensitive patient population compared with J&J’s
In Lilly’s Libretto-432 ASCO…
In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Seeking a share of the first-line…
Seeking a share of the first-line diffuse B-cell lymphoma market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-CHOP regimen and Roche’s Polivy—that’s at least
Pharma companies need to…
Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to 49 years, an Omnicom Health report found.
Philips has integrated animated…
Philips has integrated animated Disney characters and stories into MRI machines to make imaging scans more comforting and engaging for children.
With a pediatric approval in hand…
With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insulin powder.
List prices for 25 top brand-name…
List prices for 25 top brand-name drugs rose an average of 81% after launch in the U.S., while prices for the same medicines fell an average of 13% abroad, according to a new AARP analysis.
About three years after a phase 3…
About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 lung cancer market, Dizal Pharma has data showing its small molecule drug may have what it
AstraZeneca has fired another shot…
AstraZeneca has fired another shot in its bladder cancer competition with Merck’s Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients
Scientists Find a Potential Cure for Chronic Hepatitis B
Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these patients.
A group of over 20 global pharma…
A group of over 20 global pharma leaders met with Japan's Prime Minister Sanae Takaichi to address Japan's declining share of biopharma R&D.
The top pharmacy benefit manager…
The top pharmacy benefit manager in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, allowing a significant number of patients to gain access to the drugs through their existing insurance.
As China-developed assets gain…
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to curb the trend before the U.S. loses key biotechnology capabilities. During these discussions, it was only fitting that Pfizer struck an
PharmaEssentia has hired Eric…
PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare blood cancer drug Besremi to a much wider market.
Kaléo has launched the “AUVI-Q…
Kaléo has launched the “AUVI-Q Speaks Up” campaign to share patients’, caregivers’ and healthcare providers’ stories about life with severe allergies.
Gifthealth’s CCO explains why DTP…
Gifthealth's CCO explains why DTP is no longer optional, - and how pharma teams can unlock its full potential.
As AbbVie continues to capitalize…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate Elahere, another of the acquired company’s clinical assets has crossed the FDA finish line.
Viridian aims to challenge Amgen…
Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.